Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
Enter any scientific lab and among the first tools
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
Drug firm FDC Ltd on Tuesday said it has established two variants of this COVID-19 drug Favipiravir under the brand names PiFLU and Favenza. The Drug Controller General of India (DCGI) had previously approved the use of Favipiravir, an off patent, oral antiviral drug that’s been demonstrated to quicken clinical healing from COVID-19 patients with mild to moderate symptoms, FDC said in a statement.
“Early diagnosis and treatment will aid in arresting the deteriorating condition of patients, and we’ll be working with the authorities and health care fraternity to create Favenza and PiFLU available across the nation” FDC spokesperson Mayank Tikkha said.
Both the products are currently available across the nation, the company said.
The price per tablet computer is Rs 55 for both the versions, it included.
